ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

Commodity Zero-Fee Gala

Aktis Oncology, Inc. (AKTS)

NASDAQ

$19,41

$-0,46

(-2,32%)

Aktis Oncology, Inc. (AKTS) Live Price Chart

Page last updated: 2026-02-06 17:53:00

Key Market Data

Market Cap	$905,19M
Open	$19,31
High	$29,16
Low	$0,03
Previous Close	$19,57
Price Change	$-0,46
Percentage Change	-2,32%
Volume	75K

Aktis Oncology, Inc. (AKTS) Stock Price Today

Aktis Oncology, Inc. (AKTS) is currently trading at $19,41 as of 2026-02-06 17:53:00, reflecting a -2,32% move ($-0,46) from the previous close.

In the short term, the stock has returned -1 337,05% over the past four weeks. Over the last 12 months, Aktis Oncology, Inc. has recorded a -13,37% price change, indicating a weak performance relative to the broader market.

Aktis Oncology, Inc. (AKTS) 7-Day Stock Price Changes

Over the past seven days, Aktis Oncology, Inc. has traded within a short-term range shaped by market sentiment in the sector. During this period, the stock moved from its previous closing price of $20,24 to the latest recorded price of $19,41, reflecting an intraday change of -2,32%. Daily movements highlight shifts in trading volume (75 148), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, AKTS has delivered a -1 337,05% return over the past month and a -13,37% change in the last 12 months, indicating a weak trend relative to its broader sector peers.

How to Buy Aktis Oncology, Inc. (AKTS)

You can buy and trade AKTS on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for AKTS and Execute Your Trade

Open the trading page, enter AKTS in the search bar, select the amount of AKTS you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Aktis Oncology, Inc. (AKTS)?

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.

Aktis Oncology, Inc. Information

Industry	--
Employees	--
Sector	--
Company Website	https://www.aktisoncology.com

Frequently Asked Questions (FAQ)

1.What is the current share price of Aktis Oncology, Inc.?

The latest trading price for Aktis Oncology, Inc. (Common Stock) is $ 19,41, compared with a previous closing price of $ 19,57. That means the stock has moved -2,32% so far today. Intraday price updates and recent trading activity for AKTS can be tracked on the live chart and quote section on this page.

2.Is Aktis Oncology, Inc. stock going up or down?

Looking at recent performances, AKTS has returned -1 337,05% over the past month, -13,37% over the last six months and -13,37% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe weak price momentum for Aktis Oncology, Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does AKTS currently sit relative to its 52-week high and low?

In the most recent 52-week period, Aktis Oncology, Inc. has traded between a low of $ 18,02 and a high of $ 29,16. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether AKTS is currently nearer the top or the bottom of its one-year trading band.

4.How is Aktis Oncology, Inc. classified by sector and industry?

Aktis Oncology, Inc. is classified in the -- sector, within the -- industry group and the -- industry. In practice, this means Aktis Oncology, Inc. is grouped with companies that face similar end-markets, competitive dynamics and regulatory environments. For investors, knowing AKTS's sector and industry classification helps when building diversified portfolios, comparing Aktis Oncology, Inc. with direct peers, and understanding how stock-specific risks such as -- may be influenced by broader trends in the -- sector and -- industry.

5.Where is Aktis Oncology, Inc. listed and how large is it by market value?

Aktis Oncology, Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 905,19M, the company is classified as a Small-cap stock. Market cap gives a quick sense of Aktis Oncology, Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does AKTS's EPS tell investors about its profitability?

Trailing-twelve-month EPS of -- summarises how much profit Aktis Oncology, Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track Aktis Oncology, Inc.'s financial performance over time?

To follow Aktis Oncology, Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how AKTS is performing and how the market is responding.

8.When is Aktis Oncology, Inc. expected to report earnings?

Aktis Oncology, Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for AKTS, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in Aktis Oncology, Inc.'s earnings reports?

Aktis Oncology, Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether AKTS is meeting, beating or missing expectations.

10.How can I stay informed about Aktis Oncology, Inc.'s results and guidance?

You can stay up to date on Aktis Oncology, Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for AKTS on this page helps you see how new information is being reflected in the stock.

11.Does Aktis Oncology, Inc. pay a regular cash dividend to its shareholders?

Aktis Oncology, Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of -- at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor AKTS's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for AKTS?

Based on the latest earnings data, AKTS has a dividend yield of -- and a dividend payout ratio of --. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Aktis Oncology, Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Aktis Oncology, Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is Aktis Oncology, Inc.?

Aktis Oncology, Inc. is a publicly traded company in the -- industry within the -- sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is AKTS valued in terms of P/E ratio and EPS?

Aktis Oncology, Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of --. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Aktis Oncology, Inc.'s earnings. Comparing AKTS's P/E and EPS to those of other -- companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Stocks in the Same Sector

Browse other US stocks in the same sector as Aktis Oncology, Inc.

The Walt Disney Company

DIS

Largest Market Cap

See US stocks with the highest market capitalization

Berkshire Hathaway Inc.

BRK.A

Alphabet Inc.

GOOG

Most Actively Traded

Discover today's most actively traded US stocks

Caleres Inc.

CAL

Emerson Electric Co.

EMR

DOUGLAS DYNAMICS, INC.

PLOW

Republic Services Inc.

RSG

SelectQuote, Inc.

SLQT

Top Gainers

Browse today's leading gainers in the US stock market

Bio Green Med Solution, Inc.

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

SOL

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

AKTS-to-USD Calculator

Amount

AKTS

USD

1 AKTS = 19,405 USD